Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Sun Pharma Dividend Update: What 6.6 lakh retail holders need to know after Organon deal
At the end of the March quarter, Sun Pharma had a total of 6.6 lakh small retail shareholders, or those with an authorized share capital of up to ₹2 lakh. Starting February 2022, shareholders of Sun Pharma have received ₹62 per share as dividend payouts.
Sun Pharma a trading play on dips, banks may face difficult June quarter: Dharmesh Kant
Dharmesh Kant, Head of Research at Chola Securities, said Sun Pharma’s all-cash acquisition of Organon could improve return ratios and support valuations, but may bring overall revenue growth down to single digits. He sees a trading opportunity in Sun Pharma on price dips. On banking, he said Q1 could be difficult as provisioning picks up, which may weigh on profitability even as asset quality and margins remain stable. Disclaimer: The views and tips expressed by investment experts on CNBCTV18.com are their own, not of the website or its management. CNBCTV18.com advises users to check with certified experts before taking any investment decisions.
Sun Pharma shares tumble 4% as firm closes in on $12-billion Organon acquisition. What’s spooking investors?
Shares of Sun Pharmaceutical Industries fell sharply after ET reported the company had submitted a $12-billion binding offer for Organon & Co. Investors remain cautious as the pharma major nears its biggest-ever overseas acquisition amid debt concerns and volatile global conditions.
Sun Pharma preps for $12-billion Organon bid in biggest overseas pharma M&A by Indian co
Sun Pharma is moving forward with a $12 billion offer for Organon & Co. This acquisition would be the largest for an Indian pharma company. Sun Pharma is finalizing financing for the deal. Organon specializes in women's health. The company is also facing competition from other global consortiums. This move signifies Sun Pharma's ambition to grow in innovative drug research.
Sun Pharma closes in on Organon buy, gets set for $12 billion binding bid
Due diligence is complete, financing banks & advisors picked for biggest cross border pharma M&A by Indian pharma company. 2 other global suitors in fray.
Trump tariffs hit patented drugs: Jefferies, Nomura explain impact on pharma stocks
The US has slapped up to 100% tariffs on patented drugs, sparing generics and biosimilars but exposing India’s speciality pharma players. Sun Pharma faces the steepest risk, while CDMOs like Sai Lifesciences may see selective impact. Analysts at Jefferies and Nomura expect modest to mid-single-digit earnings pressure.
IIT Roorkee inaugurates Ashok Soota Molecular Medicine Facility at BSBE to advance translational biomedical research
IIT Roorkee has launched the Ashok Soota Molecular Medicine Facility, a state-of-the-art platform for advanced biomedical research, drug discovery, and diagnostics. This integrated facility, equipped with advanced instrumentation, will accelerate translational research and contribute to national healthcare priorities and global scientific advancements.
Nomura’s Saion Mukherjee picks Dr Reddy’s as top pharma bet amid semaglutide opportunity
Saion Mukherjee, Managing Director & Head of Equity Research at Nomura says Indian pharmaceutical companies are preparing to tap the opportunity as semaglutide goes off patent. While several large firms such as Sun Pharma, Lupin and Zydus could benefit from the growing diabetes and obesity drug market, Mukherjee highlighted Dr Reddy’s as his top pick in the sector. He said the opportunity will play out across domestic and global markets, with semaglutide likely to become an important growth driver for Indian pharma companies in the coming years.
CCL Products, Sai Life Sciences on Mayuresh Joshi’s watchlist for earnings strength
Mayuresh Joshi, Director of Research at Marketsmith India, is watching earnings-resilient sectors such as consumer discretionary, banking, and pharmaceuticals as market remains volatile. Along with CCL Products and Sai Life Sciences, Strides Pharma Science and ICICI Bank are on his watchlist, while Vishal Mega Mart remains a domestic consumption play worth tracking.
UPL To Integrate Indian, Overseas Crop Protection Business Into Single Entity
This integrated business will benefit from a strong manufacturing base, advanced research capabilities, a broad portfolio of registered products and brands across multiple geographies and independent management, UPL says.
Closing Bell: Sensex, Nifty end flat amid volatility; pharma, oil & gas gain, media falls
Bharat Electronics, Adani Ports, Sun Pharma, Bharti Airtel, Maruti Suzuki were among major gainers on the Sensex, while losers were Power Grid Corporation, Trent, Bajaj Finserv, HDFC Bank and Eternal. Among sectors, auto, pharma, oil & gas, PSU Bank telecom, metal added 0.4-1%, while media index shed 0.7%. Nifty Midcap index rose 0.6%, while smallcap index ended flat.
Trade Spotlight: How should you trade Torrent Power, Bajaj Auto, Hindustan Aeronautics, Sun Pharma, PFC, Aditya Birla Capital, and others on June 23?
The market trend remains healthy, but a sustained close above long-term moving averages is needed for further sharp upside. Below are some short-term trading ideas to consider.